Ugur Sahin and Özlem Türeci, the pioneering founders of Biontech, have announced their departure from the company that gained worldwide recognition during the COVID-19 pandemic. Their exit, which is planned by the end of the year, marks not only a significant transition for the pair but also implications for Biontech, where they currently hold around a 15% share. Biontech has confirmed the news, outlining that this change coincides with the expiration of their current contracts.

The duo plans to establish a new biotechnology company that will focus on developing the next generation of mRNA-based medicines. This strategic move signals their continued commitment to the field of biopharmaceuticals, even as they step back from their roles at Biontech. In a planned collaboration, Biontech will transfer certain rights and mRNA technologies to the new venture in exchange for a minority stake in the startup alongside licensing fees including milestone payments.

This transition highlights the evolving landscape of biopharmaceutical innovation. As mRNA technology continues to show potential beyond vaccines into therapies for various diseases, Sahin and Türeci's new venture may influence future developments in the industry. Their departure raises questions about the future direction of Biontech and the ongoing role of its founders as they venture into new territory in a highly competitive field.